-
Je něco špatně v tomto záznamu ?
Spironolactone differently influences remodeling of the left ventricle and aorta in L-NAME-induced hypertension
F. Simko, J. Matúsková, I. Lupták, T. Pincíková, K. Krajcírovicová, S. Stvrtina, J. Pomsár, V. Pelouch, L. Paulis, O. Pechánová
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Directory of Open Access Journals
od 1991
Free Medical Journals
od 1998
ProQuest Central
od 2005-01-01
Medline Complete (EBSCOhost)
od 2006-01-01
Nursing & Allied Health Database (ProQuest)
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1998
- MeSH
- antagonisté mineralokortikoidních receptorů farmakologie terapeutické užití MeSH
- antihypertenziva farmakologie terapeutické užití MeSH
- aorta účinky léků patologie patofyziologie MeSH
- časové faktory MeSH
- hypertenze chemicky indukované komplikace farmakoterapie metabolismus patologie patofyziologie MeSH
- hypertrofie levé komory srdeční farmakoterapie etiologie metabolismus patologie patofyziologie MeSH
- krevní tlak účinky léků MeSH
- krysa rodu rattus MeSH
- ledviny účinky léků enzymologie MeSH
- NG-nitroargininmethylester MeSH
- oxid dusnatý metabolismus MeSH
- potkani Wistar MeSH
- proliferace buněk účinky léků MeSH
- remodelace komor účinky léků MeSH
- replikace DNA účinky léků MeSH
- spironolakton farmakologie terapeutické užití MeSH
- srdeční komory účinky léků enzymologie MeSH
- synthasa oxidu dusnatého antagonisté a inhibitory metabolismus MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Aldosterone receptor antagonist, spironolactone, has been shown to prevent remodeling of the heart in several models of left ventricular hypertrophy. The aim of the present study was to determine whether the treatment with spironolactone can prevent hypertension, reduction of tissue nitric oxide synthase activity and left ventricular (LV) and aortic remodeling in N(G)-nitro-L-arginine methyl ester (L-NAME)-induced hypertension. Four groups of rats were investigated: control, spironolactone (200 mg/kg), L-NAME (40 mg/kg) and L-NAME + spironolactone (in corresponding dosage). Animals were studied after 5 weeks of treatment. The decrease of NO-synthase activity in the LV and kidney was associated with the development of hypertension and LV hypertrophy, with increased DNA concentration in the LV, and remodeling of the aorta in the L-NAME group. Spironolactone prevented the inhibition of NO-synthase activity in the LV and kidney and partially attenuated hypertension and LVH development and the increase in DNA concentration. However, remodeling of the aorta was not prevented by spironolactone treatment. We conclude that the aldosterone receptor antagonist spironolactone improved nitric oxide production and partially prevented hypertension and LVH development without preventing hypertrophy of the aorta in NO-deficient hypertension. The reactive growth of the heart and aorta seems to be controlled by different mechanisms in L-NAME-induced hypertension.
Department of Pathophysiology Comenius University Bratislava Slovak Republic
Institute of Pathology School of Medicine Comenius University Bratislava Slovak Republic
Institute of Physiology Academy of Sciences of the Czech Republic Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13034098
- 003
- CZ-PrNML
- 005
- 20151006115928.0
- 007
- ta
- 008
- 131021s2007 xr d f 000 0|eng||
- 009
- AR
- 024 __
- $a 10.33549/physiolres.931394 $2 doi
- 035 __
- $a (PubMed)17824810
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Šimko, Fedor $u Department of Pathophysiology and Third Clinic of Medicine, Comenius University, Bratislava, Slovak Republic. fedor.simko@fmed.uniba.sk $7 xx0097039
- 245 10
- $a Spironolactone differently influences remodeling of the left ventricle and aorta in L-NAME-induced hypertension / $c F. Simko, J. Matúsková, I. Lupták, T. Pincíková, K. Krajcírovicová, S. Stvrtina, J. Pomsár, V. Pelouch, L. Paulis, O. Pechánová
- 520 9_
- $a Aldosterone receptor antagonist, spironolactone, has been shown to prevent remodeling of the heart in several models of left ventricular hypertrophy. The aim of the present study was to determine whether the treatment with spironolactone can prevent hypertension, reduction of tissue nitric oxide synthase activity and left ventricular (LV) and aortic remodeling in N(G)-nitro-L-arginine methyl ester (L-NAME)-induced hypertension. Four groups of rats were investigated: control, spironolactone (200 mg/kg), L-NAME (40 mg/kg) and L-NAME + spironolactone (in corresponding dosage). Animals were studied after 5 weeks of treatment. The decrease of NO-synthase activity in the LV and kidney was associated with the development of hypertension and LV hypertrophy, with increased DNA concentration in the LV, and remodeling of the aorta in the L-NAME group. Spironolactone prevented the inhibition of NO-synthase activity in the LV and kidney and partially attenuated hypertension and LVH development and the increase in DNA concentration. However, remodeling of the aorta was not prevented by spironolactone treatment. We conclude that the aldosterone receptor antagonist spironolactone improved nitric oxide production and partially prevented hypertension and LVH development without preventing hypertrophy of the aorta in NO-deficient hypertension. The reactive growth of the heart and aorta seems to be controlled by different mechanisms in L-NAME-induced hypertension.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antihypertenziva $x farmakologie $x terapeutické užití $7 D000959
- 650 _2
- $a aorta $x účinky léků $x patologie $x patofyziologie $7 D001011
- 650 _2
- $a krevní tlak $x účinky léků $7 D001794
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a replikace DNA $x účinky léků $7 D004261
- 650 _2
- $a srdeční komory $x účinky léků $x enzymologie $7 D006352
- 650 _2
- $a hypertenze $x chemicky indukované $x komplikace $x farmakoterapie $x metabolismus $x patologie $x patofyziologie $7 D006973
- 650 _2
- $a hypertrofie levé komory srdeční $x farmakoterapie $x etiologie $x metabolismus $x patologie $x patofyziologie $7 D017379
- 650 _2
- $a ledviny $x účinky léků $x enzymologie $7 D007668
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a antagonisté mineralokortikoidních receptorů $x farmakologie $x terapeutické užití $7 D000451
- 650 _2
- $a NG-nitroargininmethylester $7 D019331
- 650 _2
- $a oxid dusnatý $x metabolismus $7 D009569
- 650 _2
- $a synthasa oxidu dusnatého $x antagonisté a inhibitory $x metabolismus $7 D019001
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a spironolakton $x farmakologie $x terapeutické užití $7 D013148
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a remodelace komor $x účinky léků $7 D020257
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Matúšková, J. $u Department of Pathophysiology, Comenius University, Bratislava, Slovak Republic $7 _AN075350
- 700 1_
- $a Ľupták, Ivan $u Department of Pathophysiology, Comenius University, Bratislava, Slovak Republic $7 xx0078706
- 700 1_
- $a Pinčíková, Terézia $u Department of Pathophysiology, Comenius University, Bratislava, Slovak Republic $7 xx0101984
- 700 1_
- $a Krajčírovičová, Kristína $u Department of Pathophysiology, Comenius University, Bratislava, Slovak Republic $7 xx0104738
- 700 1_
- $a Štvrtina, Svetoslav $u Institute of Pathology, School of Medicine, Comenius University, Bratislava, Slovak Republic $7 xx0102705
- 700 1_
- $a Pomšár, J. $u Department of Pathophysiology, Comenius University, Bratislava, Slovak Republic $7 _AN075353
- 700 1_
- $a Pelouch, Václav, $u Department of Medical Chemistry and Biochemistry, Second Faculty of Medicine, Charles University and Center for Cardiovascular Research, Prague, Czech Republic $d 1941-2010 $7 nlk20010095562
- 700 1_
- $a Paulis, Ľudovít $u Department of Pathophysiology, Comenius University, Bratislava, Slovak Republic; Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, Bratislava, Slovak Republic $7 xx0093004
- 700 1_
- $a Pecháňová, Oľga, $u Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, Bratislava, Slovak Republic; Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic $d 1962- $7 xx0075055
- 773 0_
- $w MED00003824 $t Physiological research $x 0862-8408 $g Roč. 56,Suppl 2 (2007), s. S25-S32
- 773 0_
- $t The importance of nitric oxide in the hemodynamically overloaded circulation $x 0862-8408 $g Roč. 56,Suppl 2 (2007), s. S25-S32 $w MED00163484
- 856 41
- $u http://www.biomed.cas.cz/physiolres/pdf/56%20Suppl%202/56_S25.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 4120 $c 266 $y 4 $z 0
- 990 __
- $a 20131021 $b ABA008
- 991 __
- $a 20151006120113 $b ABA008
- 999 __
- $a ok $b bmc $g 999456 $s 832568
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2007 $b 56 $c Suppl 2 $d S25-S32 $i 0862-8408 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- BMC __
- $a 2007 $b 56 $c Suppl 2 $d S25-S32 $i 0862-8408 $m The importance of nitric oxide in the hemodynamically overloaded circulation $n $x MED00163484
- LZP __
- $b NLK138 $a Pubmed-20131021